AstraZeneca PLC closed 21.95% short of its 52-week high of £133.88, which the company reached on September 3rd.

We’ve written about this before, but it’s striking how the composition of the FTSE 100 is evolving. The rise of defence ...

The selection of a first-line treatment for patients with advanced EGFR -positive non-small cell lung cancer (NSCLC) has ...

AstraZeneca PLC closed 20.63% short of its 52-week high of £133.88, which the company achieved on September 3rd.

AstraZeneca’s stock market exit would be devastating blow, warns ex-chancellor - The UK is ‘a hostile environment’ for ...

AstraZeneca may have washed its hands of AZD4041 after the opioid use disorder (OUD) prospect demonstrated a potential drug-drug interaction last year, but the pharma’s development partner, Eolas T | ...

"attachment_1220866" align="aligncenter" width="1456"] A laboratory employee in a sterile environment inspecting a microscope ...

Regarding the value of this meeting of the Anglican Communion Science Commission, Dr Heather went on to say, “The discussion is important and for bishops to weigh in with their input into ethics, they ...

The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR ...

At a lymphoma conference, experts sparred about treatment options, while an outside expert highlighted the value of each approach.

Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...